WHAT: Sub-optimal riboflavin status may be more widespread than is generally recognised across the developed world, because of the reliance on dietary data only in nutrition surveys, without biomarker evidence. DERIVE will address this gap by developing accessible riboflavin biomarkers for use in population surveys globally, and by demonstrating important functional, gene-nutrient and health effects of optimal riboflavin status in Canadian, Irish and UK cohorts.
WHO: This unique partnership of scientists from three jurisdictions brings together Canadian, Irish and UK population cohorts to study novel nutrient factors, and related gene-nutrient interactions, and functional effects that influence health, including hypertension, a leading cause of mortality. Our proposal will lead to enhancements in health and disease prevention that can be marketed as a global strategy rather than one that is population specific. The partners are Mary Ward, Ulster University, Ireland (Coordinator); Yvonne Lamers, University of British Columbia, Canada; Albert Flynn, University College Cork, Ireland and Peter Weber, DSM Nutritional Products, Switzerland.
HOW: The proposed study will access bio-banked blood samples (collected under the JINGO initiative http://www.ucd.ie/jingo/) and data from one the most comprehensive dietary surveys in the EU, the Irish National Adult Nutrition Survey (www.iuna.net) as well as bio-banked specimen and data from the BC Generations Project (www.bcgenerationsproject.ca), part of the Canadian Partnership for Tomorrow Project, a major research platform for the study of disease causation.